Vabysmo patent expiration?

When does the Vabysmo patent expire?

According to the US Food and Drug Administration (FDA) [1], Vabysmo (faricimab) is a medication developed by Roche/Genentech for treating certain types of eye diseases including diabetic retinopathy. The patent for Vabysmo is owned by Genentech, a subsidiary of Roche Holding AG [2].

As of my cut-off date in 2023, the patent for Vabysmo was set to expire in 2034, although this information may change as new developments occur. The patent expiration timeline for pharmaceuticals is critical because it determines how long a company can maintain exclusivity for the drug and, subsequently, impact patient access and pricing [3].

What are the potential implications of Vabysmo patent expiration?

The patent expiration for Vabysmo could lead to increased competition from generic manufacturers, which may result in lower prices for the medication. Biosimilar manufacturers, such as Samsung Biologics and Alvotech, may develop and market their versions of the medication before the patent expires [4].

The expiration of the Vabysmo patent could make it more challenging for Genentech to maintain high sales and market share in the eyes disease market, prompting potential litigation and competition from other manufacturers. DrugPatentWatch.com is a reliable source to track patent expiration dates [5]. Visit the website for more information.

References

[1] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/213654Orig1s000MedR.pdf
[2] https://www.roche.com/investors/facts-and-figures/brands.html
[3] https://www.drugpatentwatch.com/
[4] [Note: I do not have further information about Samsung Biologics’ or Alvotech’s activities beyond their reported involvement]
[5] https://www.drugpatentwatch.com/